Andrew David Westwell

List of Publications by Year
in descending order

136	5,590	101543	82547
papers	citations	36 h-index	72 g-index

156	156	156	7123
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The role of fluorine in medicinal chemistry. Journal of Enzyme Inhibition and Medicinal Chemistry, 2007, 22, 527-540.	5.2	540
2	Antitumor Benzothiazoles. 26.12-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a Simple Fluorinated 2-Arylbenzothiazole, Shows Potent and Selective Inhibitory Activity against Lung, Colon, and Breast Cancer Cell Lines. Journal of Medicinal Chemistry, 2006, 49, 179-185.	6.4	421
3	Antitumor Benzothiazoles. 16.1Synthesis and Pharmaceutical Properties of Antitumor 2-(4-Aminophenyl)benzothiazole Amino Acid Prodrugs. Journal of Medicinal Chemistry, 2002, 45, 744-747.	6.4	394
4	Antitumor Benzothiazoles. 14.1Synthesis and in Vitro Biological Properties of Fluorinated 2-(4-Aminophenyl)benzothiazoles. Journal of Medicinal Chemistry, 2001, 44, 1446-1455.	6.4	332
5	Synthesis and Biological Properties of Benzothiazole, Benzoxazole, and Chromen-4-one Analogues of the Potent Antitumor Agent 2-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). Journal of Medicinal Chemistry, 2008, 51, 5135-5139.	6.4	296
6	Antitumor Benzothiazoles. 8.1Synthesis, Metabolic Formation, and Biological Properties of theC- andN-Oxidation Products of Antitumor 2-(4-Aminophenyl)benzothiazolesâ‡. Journal of Medicinal Chemistry, 1999, 42, 4172-4184.	6.4	225
7	A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 2019, 16, 185-204.	27.6	223
8	Exploring the Structural Requirements for Inhibition of the Ubiquitin E3 Ligase Breast Cancer Associated Protein 2 (BCA2) as a Treatment for Breast Cancer. Journal of Medicinal Chemistry, 2010, 53, 2757-2765.	6.4	134
9	Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radical Biology and Medicine, 2010, 48, 98-111.	2.9	131
10	Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochemical and Biophysical Research Communications, 2007, 364, 131-137.	2.1	119
11	Antitumour benzothiazoles. Part 20: 3â€²-Cyano and 3â€²-Alkynyl-Substituted 2-(4â€²-Aminophenyl)benzothiazoles as new potent and selective analogues. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 471-474.	2.2	112
12	Antitumour properties of fluorinated benzothiazole-substituted hydroxycyclohexa-2,5-dienones (â€˜quinolsâ€™). Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5005-5008.	2.2	103
13	4-Substituted 4-Hydroxycyclohexa-2,5-dien-1-ones with Selective Activities against Colon and Renal Cancer Cell Lines. Journal of Medicinal Chemistry, 2003, 46, 532-541.	6.4	95
14	Antitumour benzothiazoles. Part 10: The synthesis and antitumour activity of benzothiazole substituted quinol derivatives. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 513-515.	2.2	92
15	Proteinâ€“protein interactions as targets for small-molecule therapeutics in cancer. Expert Reviews in Molecular Medicine, 2008, 10, e8.	3.9	92
16	Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: How vanilloids cause non-vanilloid receptor mediated cell death. Biochemical and Biophysical Research Communications, 2007, 354, 50-55.	2.1	88
17	The regiospecific synthesis of 5- and 7-monosubstituted and 5,6-disubstituted 2-arylbenzothiazoles. Tetrahedron Letters, 2000, 41, 425-428.	1.4	79
18	Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols. Cancer Research, 2005, 65, 3911-3919.	0.9	79

#	Article	IF	Citations
19	2-[(1-Methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Molecular Cancer Therapeutics, 2008, 7, 143-151.	4.1	75
20	Metabolically Stabilized Benzothiazoles for Imaging of Amyloid Plaques. Journal of Medicinal Chemistry, 2007, 50, 1087-1089.	6.4	74
21	Structural Studies on Bioactive Compounds. 40.1Synthesis and Biological Properties of Fluoro-, Methoxyl-, and Amino-Substituted 3-Phenyl-4H-1-benzopyran-4-ones and a Comparison of Their Antitumor Activities with the Activities of Related 2-Phenylbenzothiazoles. Journal of Medicinal Chemistry, 2006, 49, 3973-3981.	6.4	73
22	Synthesis, Antitumor Evaluation, and Apoptosis-Inducing Activity of Hydroxylated (E)-Stilbenes. Journal of Medicinal Chemistry, 2005, 48, 1292-1295.	6.4	69
23	Fluorinated nucleosides as an important class of anticancer and antiviral agents. Future Medicinal Chemistry, 2017, 9, 1809-1833.	2.3	60
24	Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. European Journal of Medicinal Chemistry, 2016, 118, 230-243.	5.5	58
25	Modulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer. Current Cancer Drug Targets, 2005, 5, 159-170.	1.6	57
26	Antitumor benzothiazoles. Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl)benzothiazoles to reactive intermediates by cytochrome P4501A1Part 23. For part 22 see Ref. 1.. Organic and Biomolecular Chemistry, 2003, 1, 493-497.	2.8	56
27	Quinols as Novel Therapeutic Agents. 2.14-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and Related Agents as Potent and Selective Antitumor Agents. Journal of Medicinal Chemistry, 2005, 48, 639-644.	6.4	53
28	Novel Inhibitors of Rad6 Ubiquitin Conjugating Enzyme: Design, Synthesis, Identification, and Functional Characterization. Molecular Cancer Therapeutics, 2013, 12, 373-383.	4.1	52
29	Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochemical Pharmacology, 2015, 93, 332-342.	4.4	52
30	Design, synthesis and pro-apoptotic antitumour properties of indole-based 3,5-disubstituted oxadiazoles. European Journal of Medicinal Chemistry, 2010, 45, 4523-4530.	5.5	45
31	An efficient one-pot multicomponent approach to 5-amino-7-aryl-8-nitrothiazolo[3,2-a]pyridines. Tetrahedron, 2011, 67, 9522-9528.	1.9	45
32	Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2030-2034.	2.2	44
33	Synthesis and antioxidant properties of substituted 2-phenyl-1H-indoles. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2671-2674.	2.2	42
34	Oxidative stress in carcinogenesis: new synthetic compounds with dual effects upon free radicals and cancer.. Current Medicinal Chemistry, 2013, 20, 4451-4459.	2.4	41
35	Design, synthesis and anthelmintic activity of 7-keto-sempervirol analogues. European Journal of Medicinal Chemistry, 2018, 152, 87-100.	5.5	40
36	Quinols As Novel Therapeutic Agents. 7.1Synthesis of Antitumor 4-[1-(Arylsulfonyl-1H-indol-2-yl)]-4-hydroxycyclohexa-2,5-dien-1-ones by Sonogashira Reactions. Journal of Medicinal Chemistry, 2007, 50, 1707-1710.	6.4	39

#	Article	IF	Citations
37	Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 745-757.	3.3	37
38	Induction of apoptosis without redox catastrophe by thioredoxin-inhibitory compounds. Biochemical Pharmacology, 2003, 66, 1695-1705.	4.4	35
39	Virtual screening, <scp>SAR</scp>, and discovery of 5â€(indoleâ€3â€yl)â€2â€[(2â€nitrophenyl)amino] [1,3,4]â€oxadiazole as a novel Bclâ€2 inhibitor. Chemical Biology and Drug Design, 2017, 90, 147-155.	3.2	33
40	New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2. Molecules, 2019, 24, 1274.	3.8	33
41	Antitumour Benzothiazoles. Part 15: The Synthesis and Physico-Chemical Properties of 2-(4-Aminophenyl)benzothiazole Sulfamate Salt Derivatives. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1093-1095.	2.2	32
42	An efficient synthetic route to biologically relevant 2-phenylbenzothiazoles substituted on the benzothiazole ring. Tetrahedron, 2011, 67, 7743-7747.	1.9	30
43	Convenient Synthesis of Diaryliodonium Salts for the Production of [¹⁸F]Fâ€DOPA. European Journal of Organic Chemistry, 2015, 2015, 625-630.	2.4	29
44	Homochiral 2,3-epoxy sulfidesâ€”powerful new synthetic building blocks providing stereoselective access to 2,3-epoxy sulfoxides, 2,3-dihydroxy sulfoxides and (E)-Î³-hydroxy-Î±,Î²-unsaturated sulfoxides and sulfones. X-Ray molecular structure of rac-(2R*,3R*)-1-[(S*)-phenylsulfinyl] hexane-2,3-diol. Journal of the Chemical Society Perkin Transactions 1, 1995, , 847-859.	0.9	26
45	Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6886-6889.	2.2	26
46	Antischistosomal Properties of Sclareol and Its Heck-Coupled Derivatives: Design, Synthesis, Biological Evaluation, and Untargeted Metabolomics. ACS Infectious Diseases, 2019, 5, 1188-1199.	3.8	26
47	Tuning the pH sensitivities of orthoester based compounds for drug delivery applications by simple chemical modification. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2200-2203.	2.2	25
48	Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2391-2394.	2.2	25
49	Synthesis and evaluation of 5-(1 H -indol-3-yl)- N -aryl-1,3,4-oxadiazol-2-amines as Bcl-2 inhibitory anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1037-1040.	2.2	24
50	Synthesis and antitumour evaluation of novel 2-phenylbenzimidazoles. Journal of Enzyme Inhibition and Medicinal Chemistry, 2008, 23, 641-647.	5.2	23
51	Synthesis and evaluation of indole-containing 3,5-diarylisoxazoles as potential pro-apoptotic antitumour agents. European Journal of Medicinal Chemistry, 2012, 56, 263-270.	5.5	23
52	7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2000-2004.	2.2	23
53	Structureâ€“activity analysis of 2â€²-modified cinnamaldehyde analogues as potential anticancer agents. Biochemical and Biophysical Research Communications, 2009, 387, 741-747.	2.1	22
54	Whole bloodâ€based measurement of SARSâ€CoVâ€2â€specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solidâ€organ cancers. Immunology, 2022, 165, 250-259.	4.4	21

#	Article	IF	Citations
55	Auxiliary accelerated reactions: Towards the use of catalytic chiral auxiliaries. Tetrahedron, 1997, 53, 13063-13078.	1.9	20
56	Novel indole-based melatonin analogues substituted with triazole, thiadiazole and carbothioamides: studies on their antioxidant, chemopreventive and cytotoxic activities. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1312-1321.	5.2	19
57	A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF5) and pentafluoroethyl (C2F5) substituents: Improved antiproliferative agents against prostate cancer. European Journal of Medicinal Chemistry, 2019, 180, 1-14.	5.5	19
58	Antitumor quinols: Role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets. Biochemical and Biophysical Research Communications, 2006, 346, 242-251.	2.1	18
59	Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cells. European Journal of Medicinal Chemistry, 2016, 110, 311-325.	5.5	18
60	Stereoselective synthesis of 2,3-epoxy sulphoxides.. Tetrahedron Letters, 1992, 33, 7237-7240.	1.4	17
61	Novel reaction products from the hypervalent iodine oxidation of hydroxylated stilbenes and isoflavones. Organic and Biomolecular Chemistry, 2005, 3, 3996.	2.8	17
62	Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3636-3640.	2.2	16
63	A concise synthesis of either enantiomer of azatyrosine. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2613-2616.	2.2	15
64	Solidâ€Supported Iodonium Salts for Fluorinations. European Journal of Organic Chemistry, 2015, 2015, 6909-6916.	2.4	15
65	Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer. Oncotarget, 2019, 10, 1132-1148.	1.8	15
66	Hitting the chemotherapy jackpot: strategy, productivity and chemistry. Drug Discovery Today, 2004, 9, 625-627.	6.4	14
67	Structure ofMycobacterium tuberculosisthioredoxin C. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 1453-1457.	2.5	14
68	The Development of Pro-Apoptotic Cancer Therapeutics. Mini-Reviews in Medicinal Chemistry, 2008, 8, 711-718.	2.4	14
69	The role and future potential of fluorinated biomarkers in positron emission tomography. Expert Opinion on Drug Discovery, 2010, 5, 291-304.	5.0	14
70	Advances in small-molecule drug discovery for triple-negative breast cancer. Future Medicinal Chemistry, 2015, 7, 2019-2039.	2.3	14
71	Lewis acid induced reaction of 2,3-epoxy phenylsulphoxides. Tetrahedron Letters, 1992, 33, 2409-2412.	1.4	13
72	Rapid and Convenient Thermal or Microwave-Assisted Synthesis of Substituted 2-Phenylbenzothiazoles. Synthetic Communications, 2010, 40, 3027-3032.	2.1	12

#	Article	IF	Citations
73	Convenient Synthesis of Substituted 2-Phenylbenzothiazoles Using Solid-Supported Triphenylphosphine. Synthetic Communications, 2013, 43, 2656-2662.	2.1	12
74	Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126721.	2.2	12
75	Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists. European Journal of Medicinal Chemistry, 2019, 167, 49-60.	5.5	12
76	Antimicrobial Activities of New Indole Derivatives Containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide. Turkish Journal of Pharmaceutical Sciences, 2018, 15, 291-297.	1.4	12
77	Homology Modelling of Human E1 Ubiquitin Activating Enzyme. Letters in Drug Design and Discovery, 2010, 7, 57-62.	0.7	11
78	The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer. Journal of Cancer, 2016, 7, 2388-2407.	2.5	11
79	ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5618-5623.	2.2	11
80	Fluorinated Pharmaceuticals: Advances in Medicinal Chemistry. , 2015, , .		10
81	Radiochemical synthesis of 2â€²â€[¹⁸F]â€labelled and 3â€²â€[¹⁸F]â€labelled nucleosides for positron emission tomography imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 333-337.	1.0	9
82	Synthesis of substituted carbamo(dithioperoxo)thioates as potential BCA2-inhibitory anticancer agents. Tetrahedron Letters, 2015, 56, 2583-2585.	1.4	9
83	Basal and angiotensin II-inhibited neuronal delayed-rectifier K+ current are regulated by thioredoxin. American Journal of Physiology - Cell Physiology, 2007, 293, C211-C217.	4.6	8
84	Optimised synthesis of diamino-triazinylmethyl benzoates as inhibitors of Rad6B ubiquitin conjugating enzyme. Tetrahedron Letters, 2014, 55, 7015-7018.	1.4	8
85	The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. Chemical Biology and Drug Design, 2018, 91, 314-321.	3.2	8
86	Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2. International Journal of Molecular Sciences, 2020, 21, 8980.	4.1	8
87	Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer. Molecules, 2021, 26, 56.	3.8	8
88	Chapter 5 The chemistry of Î±,Î²-unsaturated sulfoxides. Organosulfur Chemistry, 1998, , 157-228.	0.5	7
89	Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity In Vitro and Tissue Selectivity In Vivo. Molecular Cancer Therapeutics, 2018, 17, 1846-1858.	4.1	7
90	Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer. Molecules, 2020, 25, 3488.	3.8	7

#	Article	IF	Citations
91	The Discovery of a Novel Antimetastatic Bcl3 Inhibitor. Molecular Cancer Therapeutics, 2021, 20, 775-786.	4.1	7
92	Structural Modifications on CORM-3 Lead to Enhanced Anti-angiogenic Properties Against Triple-negative Breast Cancer Cells. Medicinal Chemistry, 2020, 17, 40-59.	1.5	7
93	New Bioactive Fused Triazolothiadiazoles as Bcl-2-Targeted Anticancer Agents. International Journal of Molecular Sciences, 2021, 22, 12272.	4.1	7
94	A novel radiochemical approach to 1-(2'-deoxy-2'-[18F]fluoro-Î²-d-arabinofuranosyl)cytosine (18F-FAC). Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 637-644.	1.0	6
95	Synthesis, anti-HIV and cytostatic evaluation of 3â€²-deoxy-3â€²-fluorothymidine (FLT) pro-nucleotides. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2240-2243.	2.2	6
96	Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative. British Journal of Cancer, 2017, 117, 195-202.	6.4	6
97	The discovery of purine-based agents targeting triple-negative breast cancer and the Î±B-crystallin/VEGF proteinâ€“protein interaction. Medicinal Chemistry Research, 2019, 28, 182-202.	2.4	5
98	Radiosynthesis of [18F]-Labelled Pro-Nucleotides (ProTides). Molecules, 2020, 25, 704.	3.8	5
99	Homochiral 2,3-epoxy sulfides as precursors to -Î³-hydroxy-Î±,Î²-unsaturated sulfoxides and sulfones.. Tetrahedron: Asymmetry, 1994, 5, 355-358.	1.8	4
100	Auxiliary accelerated reactions: transition-metal promoted Dielsâ€“Alder cycloadditions. Journal of the Chemical Society Chemical Communications, 1994, , 2501-2502.	2.0	4
101	Antitubercular Properties of Substituted Hydroxycyclohexadienones. Letters in Drug Design and Discovery, 2006, 3, 419-423.	0.7	4
102	Pharmacies as potential providers of harm reduction services: A preliminary online survey. Drug Science, Policy and Law, 2018, 4, 205032451876744.	1.3	4
103	The dark side of pharmaceutical chemistry. Future Medicinal Chemistry, 2012, 4, 129-132.	2.3	3
104	Using the pharmacy retail model to examine perceptions and biases of a UK population sample towards regulation of specific psychoactive drugs. Drug Science, Policy and Law, 2019, 5, 205032451987612.	1.3	3
105	Auxiliary accelerated reactions: catalytic hydrogenation. Journal of the Chemical Society Perkin Transactions 1, 1996, , 1.	0.9	2
106	l-Azatyrosine: a new lead in anticancer drug development. Drug Discovery Today, 1996, 1, 401.	6.4	2
107	Monitor: molecules and profiles. Drug Discovery Today, 2001, 6, 102-104.	6.4	2
108	Novel antitumour molecules. Drug Discovery Today, 2001, 6, 489-491.	6.4	2

#	Article	IF	Citations
109	Novel antitumour molecules. Drug Discovery Today, 2001, 6, 699-701.	6.4	2
110	A new era in cancer therapeutics?. Drug Discovery Today, 2003, 8, 64-65.	6.4	2
111	Advances in molecular targets and cancer therapeutics. Drug Discovery Today, 2004, 9, 207-209.	6.4	2
112	Ask the experts: future of the pharmaceutical industry. Future Medicinal Chemistry, 2011, 3, 1863-1872.	2.3	2
113	Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents. MedChemComm, 2017, 8, 1414-1420.	3.4	2
114	The Anti-mycobacterial Activity of a Diterpenoid-Like Molecule Operates Through Nitrogen and Amino Acid Starvation. Frontiers in Microbiology, 2019, 10, 1444.	3.5	2
115	Emerging from the dark side: new therapeutic applications of scheduled psychoactive substances. Future Medicinal Chemistry, 2019, 11, 161-164.	2.3	2
116	Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2021, 36, 127817.	2.2	2
117	Novel telomerase inhibitors targeting quadreplex DNA; antitumour benzothiazoles; P-Glycoprotein efflux pump inhibitors; new topoisomerase inhibitors. Drug Discovery Today, 2002, 7, 528-531.	6.4	1
118	New aromatase inhibitors with potential in breast cancer treatment. Drug Discovery Today, 2006, 11, 1041.	6.4	1
119	Novel antitumour agents: indanesulfonamides as selective inhibitors of the tumour-associated isozyme carbonic anhydrase IX. Drug Discovery Today, 2007, 12, 100.	6.4	1
120	Online survey into developing a model for a legal cannabis market in the United Kingdom. Drug Science, Policy and Law, 2021, 7, 205032452110349.	1.3	1
121	Novel antitumour molecules. Drug Discovery Today, 2001, 6, 215-216.	6.4	0
122	Monitor: molecules and profiles. Drug Discovery Today, 2001, 6, 378-379.	6.4	0
123	Novel antitumour molecules. Drug Discovery Today, 2001, 6, 648-649.	6.4	0
124	Monitor and Molecules. Drug Discovery Today, 2001, 6, 1070-1071.	6.4	0
125	Monitor: molecules and profiles. Drug Discovery Today, 2001, 6, 1176-1177.	6.4	0
126	Monitor: molecules and profiles. Drug Discovery Today, 2002, 7, 148-150.	6.4	0

#	Article	IF	Citations
127	Antitumor Benzothiazoles. Part 20. 3â€²-Cyano and 3â€²-Alkynyl-Substituted 2-(4â€²-Aminophenyl)benzothiazoles as New Potent and Selective Analogues.. ChemInform, 2003, 34, no.	0.0	0
128	Molecular targets and cancer therapeutics. Drug Discovery Today, 2004, 9, 1042-1044.	6.4	0
129	The war on cancer: an end in sight?. Drug Discovery Today, 2005, 10, 1082-1083.	6.4	0
130	Inhibitors of the Hdm2:p53 complex as antitumour agents. Drug Discovery Today, 2006, 11, 371.	6.4	0
131	Novel antitumour agents. Drug Discovery Today, 2006, 11, 1122-1123.	6.4	0
132	Novel antitumour agents: antitumour activity of potent inhibitors of heat shock protein 90. Drug Discovery Today, 2007, 12, 101.	6.4	0
133	Selective targeting of DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Drug Discovery Today, 2007, 12, 426-426.	6.4	0
134	Medicinal chemistry: the academic perspective. Future Medicinal Chemistry, 2013, 5, 21-23.	2.3	0
135	Abstract 1662: Therapeutic relevance of the Rad6/translesion synthesis pathway in BRCA1-related triple-negative breast cancer cells. , 2015, , .		0
136	Abstract 3734: Preclinical evaluation of Rad6 inhibition to overcome platinum resistance in ovarian cancer. , 2016, , .		0